1. Yumino D, Wang H, Floras JS, et al. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. J Card Fail. 2009;15(4):279-285.
2. Benjamin EJ, Muntner P, Alonso A, et at. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254-e743.
3. Pierre-Louis B, Rodriques S, Gorospe V, et al. Clinical factors associated with early readmission among acutely decompensated heart failure patients. Arch Med Sci. 2016;12(3):538-545.
4. National Center for Health Statistics. Health, United States, 2020-2021. Emergency Department (ED) Visits. Available at https://www.cdc.gov/nchs/hus/topics/hospitalization.htm. Last accessed November 10, 2022.
5. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37(2):386-391.
6. Agarwal MA, Fonarow GC, Ziaeian B. National trends in heart failure hospitalizations and readmissions from 2010 to 2017. JAMA Cardiol. 2021;6:952-956.
7. Mehra M. Changing climate in heart failure: towards a new era. Cardiovasc Rev Rep. 1998;19(5):15-22.
8. Centers for Disease Control and Prevention. Heart Failure. Available at https://www.cdc.gov/heartdisease/heart_failure.htm. Last accessed November 10, 2022.
9. Hall MJ, Levant S, DeFrances CJ. Hospitalization for Congestive Heart Failure: United States, 2000–2010. NCHS Data Brief, No. 108. Hyattsville, MD: National Center for Health Statistics; 2012.
10. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(8):e895-e1032.
11. American Heart Association. Classes of Heart Failure. Available at https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure. Last accessed November 10, 2022.
13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and risk of heart failure. N Engl J Med. 2002;347(5):305-313.
14. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008;26(7):1477-1486.
15. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002;136(3):181-191.
17. Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med. 2013;159(11):746-757.
18. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210-1219.
19. Silver M. The heart failure clinic. In: Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 695-700.
20. Hoyt R, Bowling LS. Reducing readmissions for congestive heart failure. Am Fam Phys. 2001;63(8):1593-1599.
21. Colucci WS. The sympathetic nervous system in heart failure. In: Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 189-198.
22. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
23. Saito Y, Nakao K, Itoh H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158(2):360-368.
24. Januzzi JL, van Kimmenade R, Lainchbury J. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1,256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-337.
25. Chen HH, Burnett, JC. The natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2(3):198-205.
26. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. AmHeart J. 2001;141(3):367-374.
27. Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. Rev Cardiovasc Med. 2001;2(2):S2-S6.
28. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002;3(Suppl 4):S10-S17.
29. Maisel AS. B-type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. Rev Cardiovasc Med. 2001;2(Suppl 2):S13-S18.
30. Burger MR, Burger AJ. BNP in decompensated heart failure: diagnostic, prognostic, and therapeutic potential. Curr Opin Invest Drugs. 2001;2(7):929-935.
31. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111(5):406-416.
32. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43(6):1019-1026.
33. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74.
34. Sharma R, Anker SD. Immune and neurohormonal pathways in chronic heart failure. Congest Heart Fail. 2002;8:23-28.
35. Cody JR. Hormonal alterations in heart failure. In: Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 199-212.
36. Rosner MH, Ronco C. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism. Congest Heart Fail. 2010;16(Suppl 1):S7-S14.
37. Vishram-Nielsen JK, Gustafsson F. Vasopressin and vasopressin antagonists in heart failure. Handb Exp Pharmacol. 2017;243:307-328.
38. Iovino M, Iocoviello M, De Pergola G, et al. Vasopressin in heart failure. Endocr Metab Immune Disord Drug Targets. 2018;18(5):458-465.
39. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343(8895):440-444.
40. Dao Q, Kriswhnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol. 2001;37(2):379-385.
41. Jaltotage B, Dwivedi G, Ooi DEL, Mahadavan G. The utility of circulating and imaging biomarkers alone and in combination in heart failure. Curr Cardiol Rev. 2021;17(5):e160721193557.
42. Alcidi G, Goffredo G, Correale M, Brunetti ND, Iacoviello M. Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure. J Clin Med. 2022;11(11):3192.
43. Cho DH, Son JW, Lee CJ, et al. Prognostic value of short-term follow-up of multiple biomarkers after discharge in hospitalized patients with acute heart failure (POSTBIO-HF): rationale and study design. Int J Heart Fail. 2022;4(2):110-116.
44. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635-641.
45. Dhaliwal AS, Deswal A, Pritchett A, et al. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009;15(4):293-298.
46. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-3726.
47. Karlström P, Dahlström U, Boman K, Alehagen U. Responder to BNP-guided treatment in heart failure. The process of defining a responder. Scand Cardiovasc J. 2015;49(6):316-324.
48. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
49. Cleveland Clinic. NT-proB-type Natriuretic Peptide (BNP). Available at https://my.clevelandclinic.org/health/diagnostics/16814-nt-prob-type-natriuretic-peptide-bnp. Last accessed November 10, 2022.
50. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845-1853.
51. Konstam MA, Pina I, Lindenfeld J, Packer M. A device is not a drug. J Card Fail. 2003;9(3):155-157.
52. Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail. 2006;12(5):327-332.
53. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Web Addenda. Available at https://www.escardio.org/static_file/Escardio/Guidelines/ehw128_Addenda.pdf. Last accessed November 10, 2022.
54. Udelson JE, Pressler SJ, Sackner-Berstein J, et al. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the compliance and quality of life study comparing once-daily controlled-release carvedilol CR and twice-daily immediate-release carvedilol IR in patients with heart failure (CASPER) trial. J Card Fail. 2009;15(5):385-393.
55. Helber I, Dos Santos AA, Antonio EL, et al. Digitoxin prolongs survival of female rats with heart failure due to large myocardial infarction. J Card Fail. 2009;15(9):798-804.
56. Picollo CT, Dos Santos AA, Antonio EL, et al. Digitoxin attenuates heart failure, reduces myocardial hypertrophy, and preserves the calcium-binding proteins in infarcted rats. J Cardiovasc Pharmacol Ther. 2020;25(3):265-272.
57. Ouzounian M, Tu JV, Austin PC, Chong A, Liu PP, Lee DS. Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail. 2009;15(3):241-248.
58. Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015;36(24):1536-1546.
59. LexiComp Online. Available at https://online.lexi.com/lco/action/home. Last accessed November 10, 2022.
60. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
61. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531-1540.
62. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005 293:1900-1905.
63. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
64. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation. 2005;112(12):e154-e235.
65. Abraham WT, Chin MH, et al. ACC/AHA. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-e479.
66. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32-43.
67. Mearns BM. Heart failure: nesiritide safe but provides little benefit over existing therapies in acute decompensated heart failure.Nat Rev Cariol. 2011;8(9):482.
68. Salzberg SP, In patients hospitalized with acute heart failure, nesiritide, compared with placebo, is not associated with improvements in dyspnea or 30-day rehospitalization or mortality. Evid Based Med. 2012;17(2):53-54.
69. Kociol RD, Konstam MA. Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure. Am J Kidney Dis. 2012;60(1):8-11.
70. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Corlanor to Treat Heart Failure. Available at https://wayback.archive-it.org/7993/20170406032050/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm. Last accessed November 10, 2022.
71. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation. 2016;134:e282-e293.
72. Solomon SD, McMurray JJV, Anana IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New Engl J Med. 2019;381(17):1609-1620.
73. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
74. Nicolas D, Kerndt CC, Reed M. Sacubitril/Valsartan. In: StatPearls [Internet]; Treasure Island, FL: 2022.
75. U.S. Food and Drug Administration. FDA Approves New Treatment for a Type of Heart Failure. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure. Last accessed November 10, 2022.
76. U.S. Food and Drug Administration. FDA Approves Treatment for Wider Range of Patients with Heart Failure. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure. Last accessed November 10, 2022.
77. Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100933.
78. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461.
79. Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025-1029.
80. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61:2108-2117.
81. Yan Y, Liu B, Du J, et al. SGLT2I versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(3):2210-2219.
82. Aimo A, Pateras K, Stamatelopoulos K, et al. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2I in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021;35(5):1067-1076.
83. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(16):e147-e239.
84. Kumar UN, Saxon LA. Ventricular resynchronization: a promising therapy for heart failure. Am J Geriatr Cardiol. 2003;12(1):41-48.
85. Jeevanantham V, Daubert JP, Zareba W. Cardiac resynchronization therapy in heart failure patients: an update. Cardiol J. 2009;16(3):197-209.
86. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure.N Engl J Med. 2005;352(15):1539-1549.
87. Chen Y, Duan C, Liu F, Shen S, Chen P, Bin J. Impact of etiology on the outcomes in heart failure patients treated with cardiac resynchronization therapy: a meta-analysis. PLoS One. 2014;9(4):e94614.
88. Linde C, Abraham WT, Gold MR, Daubert C; REVERSE Study Group. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010;56(22):1826-1831.
89. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150.
90. Chen JS, Niu XW, Chen FM, Yao YL. Etiologic impact on difference on clinical outcomes of patients with heart failure after cardiac resynchronization therapy: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(52):e13725.
91. Mayo Clinic. Implantable Cardioverter Defibrillators (ICDs). Available at https://www.mayoclinic.org/tests-procedures/implantable-cardioverter-defibrillators/about/pac-20384692. Last accessed November 10, 2022.
92. Brady DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289(6):730-740.
93. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-1338.
94. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395-1405.
95. Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36:1983-1989.
96. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61(12):1259-1267.
97. Reynolds CR, Jessup M. Translating the benefits of cardiac resynchronization therapy widely and wisely: challenges remain. Ann Intern Med. 2011;154(6):436-438.
98. Bank AJ, Gage RM, Olshansky B. On the underutilization of cardiac resynchronization therapy. J Card Fail. 2014;20(9):696-705.
99. University of South Florida Health. Most Eligible Patients Miss Out on Cardiac Resynchronization Therapy for Heart Failure. Available at https://www.sciencedaily.com/releases/2009/12/091211181727.htm. Last accessed November 10, 2022.
100. University of Minnesota, Office for Technology Commercialization. Minnesota Living With Heart Failure Questionnaire. Available at http://license.umn.edu/technologies/94019_minnesota-living-with-heart-failure-questionnaire-mlhfq. Last accessed November 10, 2022.
101. U.S. Food and Drug Administration. Press Release: FDA Approves New Device to Improve Symptoms in Patients with Advanced Heart Failure. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-device-improve-symptoms-patients-advanced-heart-failure. Last accessed November 10, 2022.
102. Food and Drug Administration. Breakthrough Devices Program. Available at https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program. Last accessed November 10, 2022.
103. U.S. Food and Drug Administration. FDA News Release. FDA Approves New Device for Treating Moderate to Severe Chronic Heart Failure in Patients. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-device-treating-moderate-severe-chronic-heart-failure-patients. Last accessed November 10, 2022.
104. Han JJ, Acker MA, Atluri P. Left ventricular assist devices: synergistic model between technology and medicine. Circulation. 2018;138:2841-2851.
105. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165.
106. Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail. 2013;1(5):400-408.
107. Strobeck JE, Silver MA, Ventura H. Impedance cardiography: noninvasive measurement of cardiac stroke volume and thoracic fluid content. Congestive Heart Fail. 2000;6(2):3-6.
108. Shochat MK, Shotan A, Blondheim DS, et al. Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients: a randomized controlled rial (IMPEDANCE-HF) trial. J Card Fail. 2016;22(9):713-722.
109. de Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007;9:1205-1211.
110. Fonarow GC, Yancy CW, Heywood JT, et al. Adherence to heart failure quality-of-care indicators in U.S. hospitals: analysis of the ADHERE registry. Arch Intern Med. 2005;165:1469-1477.
111. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail. 2008;1:98-106.
112. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double blind, randomized controlled clinical trial. Lancet. 2005;366(9502):2005-2011.
113. Albert NM, Fonarow GC, Yancy CW, et al. Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Am Heart J. 2010;159(2):238-244.
114. Ahmed A. Quality and outcomes of heart failure care in older adults: role of multidisciplinary disease-management programs. J Am Geriatr Soc. 2002;50(9):1590-1593.
115. Thomas R, Huntley A, Mann M, et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Heart. 2013;99(4):233-239.
116. Conte MR, Mainardi L, Iazzolino E, et al. Outpatient medical and nurse management program in patients with chronic heart failure in a large territorial area in Piedmont: four years of follow-up. Ital Heart J Suppl. 2005;6(12):812-820.
117. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002;39:83-89.
118. Koelling TM, Johnson ML, Cody RJ, et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005;111:179-185.
119. Smith CE, Piamjariyakul U, Dalton KM, Russell C, Wick J, Ellerbeck EF. Nurse-led multidisciplinary heart failure group clinic appointments: methods, materials, and outcomes used in the clinical trial. J Cardiovasc Nurs. 2015;30(4 Suppl 1):S25-S34.
120. Albert NM, Young JB. Heart failure disease management: a team approach. Cleve Clin J Med. 2001;68(1):53-62.
121. Akshay SD, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126:501-506.
122. Hersh AM, Masoudi FA, Allen LA. Postdischarge environment following heart failure hospitalization: expanding the view of hospital readmission. J Am Heart Assoc. 2013;2:e000116.
123. Bales AC, Sorrentino MJ. Causes of congestive heart failure: prompt diagnosis may affect prognosis. Postgrad Med. 1997;101(1):44-49, 54-56.
124. Hershberger RE, Ni H, Nauman DJ, et al. Prospective evaluation of an outpatient heart failure management program. J Card Fail. 2001;7(1):64-74.
125. Henrick A. Cost-effective outpatient management of persons with heart failure. Prog Cardiovasc Nurs. 2001;16(2):50-56.
126. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7-e22.
127. Kosseim L, Pifer E, Zimmer R. Effective management of complex heart failure. Postgrad Med. 1999;105(6):17-23.
128. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-1450.
129. Zhu Y, Chen Z, Chen S, Fu G, Wang Y. combined effects of physical activity and sedentary behavior on all-cause mortality in heart failure patients: a cohort study of National Health and Nutrition Examination Survey analysis. Front Cardiovasc Med. 2022;14:9:1027995.
130. National Institutes of Health. Exercise Benefits Patients with Chronic Heart Failure. Available at https://www.nih.gov/news-events/nih-research-matters/exercise-benefits-patients-chronic-heart-failure. Last accessed November 10, 2022.
131. Grady KL, Dracup K, Kennedy G, et al. Team management of patients with heart failure: a statement for healthcare professionals from the Cardiovascular Nursing Council of the American Heart Association. Circulation. 2000;102(19):2443-2456.
132. Polikandrioti M, Christou A, Morou Z, Kotronoulas G, Evagelou H, Kyritsi H. Evaluation of depression in patients with heart failure. Health Sci J. 2010;4(1):37-47.
133. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38(1):199-205.
134. Artinian NT, Artinian CG, Saunders MM. Identifying and treating depression in patients with heart failure. J Cardiovasc Nurs. 2004;19(6 Suppl):S47-S56.
135. Watson K, Summers KM. Depression in patients with heart failure: clinical implications and management. Pharmacotherapy. 2009;29(1):49-63.
136. Persell SD, Baker DW. Primary prevention of heart failure. In: Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 541-556.
137. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74.
138. Perez AL, Grodin JL, Wu Y, et al. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. Eur J Heart Fail. 2016;18(3):290-297.
139. Diez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017;19(2):167-176.
140. Eisen HJ. Patient Education: Heart Transplantation (Beyond the Basics). Available at https://www.uptodate.com/contents/heart-transplantation-beyond-the-basics. Last accessed November 10, 2022.
141. Special Issue: OPTN/SRTR Annual Data Report 2020. Available at https://onlinelibrary.wiley.com/toc/16006143/2022/22/S2. Last accessed November 10, 2022.
142. Taylor D, Ott H. Cardiovascular cell therapy overview: realistic targets in 2006. In: Perin EC, Silva GV, Willerson JT (eds). An Essential Guide to Cardiac Cell Therapy. Informa Healthcare; 2006: 83-92.
143. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem cell therapy in Heart failure) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338.
144. The Joint Commission. Disease-Specific Care Certification. Available at https://www.jointcommission.org/what-we-offer/certification/certifications-by-setting/hospital-certifications/disease-specific-care-certification/. Last accessed November 10, 2022.
145. Specifications Manual for Joint Commission National Quality Measures (v2018A). Advanced Certification Heart Failure (ACHF). Available at https://manual.jointcommission.org/releases/TJC2018A/AdvancedCertificationHeartFailure.html. Last accessed November 10, 2022.
146. The Joint Commission. Advanced Heart Failure. Available at https://www.jointcommission.org/what-we-offer/certification/certifications-by-setting/hospital-certifications/cardiac-certification/advanced-cardiac/advanced-heart-failure/. Last accessed November 10, 2022.
147. The American Heart Association. Get With the Guidelines Heart Failure. Available at https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-heart-failure. Last accessed November 10, 2022.
148. Zoler ML. FDA Approves New Drug, Sotagliflozin, for Heart Failure. Available at https://www.medscape.com/viewarticle/992518. Last accessed February 9, 2024.
1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. Available at https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063. Last accessed November 21, 2022.
2. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA). European Heart Journal. 2021;42(35):3427-3520. Available at https://academic.oup.com/eurheartj/article/42/35/3427/6358547. Last accessed November 21, 2022.
Mention of commercial products does not indicate endorsement.